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Abstract 
 Ovarian cancer is the deadliest of all female gynecological cancers and the fifth leading 
cause of cancer-related death in women. Lack of early detection and treatment failure are the 
major contributors to ovarian cancer death in women. Understanding ovarian cancer at the 
molecular level will help provide better treatment options, such as targeted therapies. Nearly 
sixty percent of women are diagnosed at late stage ovarian cancer. TP53 is the most commonly 
mutated gene in ovarian cancer as well as in all other cancers. However, there are subsets of 
ovarian cancer patients with wild-type TP53, and we would like to understand the molecular and 
cellular mechanisms that disable the transcriptional functions of p53 in those patients. Wild-type 
p53 is the transcription factor that activates sets of genes to respond to various types of cellular 
and molecular stress and to maintain genomic stability in normal cells. The major function of 
wild-type p53 is the transcriptional activation of genes that are involved in cell cycle arrest to 
repair DNA damage and cell death if the damage is beyond repair in cells. However, the p53 
transcriptional functions of cell cycle arrest and cell death are not observed in those ovarian 
cancer patients with wild-type TP53 and the genes inhibiting transcriptional activities of p53 are 
not well studied. Additionally, our understanding of negative regulators of p53 in cell activity is 
not complete, and identifying those regulators may provide new insights into how the p53 
pathway can be deregulated in tumors without mutations in TP53. For that purpose, we 
performed forward genetic screening using a patient-derived pool cDNA library constructed with 
pRetro-LIB vector in wild-type TP53 ovarian cancer cells to identify the potential negative 
regulators of p53. 
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First, we tested our method of screening in wild-type TP53 ovarian cancer cells to prove 
the concept of our experimental approach. We found that using modified 293T cells (Phoenix 
AMPHO) with spin-fection method overcame the low transfection efficiency of retroviral 
particles in wild-type TP53 ovarian cancer cells (A2780). In normal cells, p53 is present at 
relatively low levels because of the negative feedback loop between Mdm2 and p53. To induce 
the p53 level in ovarian cancer cells with wild-type TP53, we used the small molecule inhibitor, 
Nutlin-3a. Nutlin-3a blocks the interaction between Mdm2 and p53, thereby allowing the 
stabilization of p53 in ovarian cancer cells. Stabilized p53 transactivates genes that initiate cell 
cycle arrest or cell death. Accordingly, Nutlin-3a suppresses the growth of cancer cells with 
wild-type TP53. We used this system to screen for exogenous genes from the patient-derived 
cDNA library that block Nutlin-3a-mediated growth suppression in A2780 cancer cells. 
 The screen identified three candidate genes (NIFK, GXYLT 1, and SACS) that prevent the 
Nutlin-3a-induced growth suppression in A2780 cancer cells, and NIFK (also known as 
Nucleolar Protein Interacting with the FHA Domain of MKI67 or MKI67IP) was identified in 
four independent screening experiments. NIFK encodes a protein that interacts with the 
forkhead-associated domain of the Ki-67 antigen and has been implicated in ribosome 
biogenesis, e.g., pre-ribosomal RNA processing and ribosome assembly. NIFK also associates 
with pre-mRNAs. However, the potential association between NIFK and p53 in ovarian cancer is 
unknown. We evaluated the level of NIFK, p53, and Mdm2 in NIFK-overexpressing ovarian 
cancer cells. We found that the dose-dependent effect of NIFK expression in preventing the 
Nutlin-3a-induced growth suppression in A2780 cells. Our results suggest that NIFK overcomes 
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the growth arrest by functional p53 induced by Nutlin-3a, and NIFK negatively regulates p53 
pathway in ovarian cancer cells. 
 In summary, our studies showed that NIFK overexpression cells play a role in cell 
survival, proliferation and the negative regulation of p53 in ovarian cancer cells, and this should 
be further explored to understand the molecular function of NIFK. 
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Introduction 
1.1 Ovarian cancer 
Ovarian cancer ranks fifth in cancer deaths and is accountable for more than other female 
reproductive-related cancer deaths in the United States alone (American Cancer Society). The 
lifetime risk for a woman of having ovarian cancer is 1 in 78 or 1.3% in women, and the median 
age of a person with ovarian cancer at the time of diagnosis is 63 years (Siegel et al., 2018). 
There are no obvious risk factors that are related to ovarian cancer and the only known strongest 
risk factor is a family history of breast and ovarian cancer (Siegel et al., 2018). According to the 
American Cancer Society, there will be approximately 22,240 new cases of ovarian cancer 
diagnosed in 2018 and 14,070 ovarian cancer-related death in the U.S. alone. Currently, ovarian 
cancer is accountable for 2.5% of all cancer cases, but 5% of all cancer-related deaths in females 
(Siegel, Miller, and Jemal 2018). 
Ovarian cancer is the most lethal gynecologic cancer among women’s cancers due to the 
lack of early detection, limited understanding of disease origin and no effective treatment for the 
disease. Early detection is still a challenge in ovarian cancer because the disease is normally 
asymptomatic before the tumor is spread to other distant organs such as bowel and omentum 
(George, Garcia, and Slomovitz 2016). The quest for the discovery of precursor lesions in 
ovarian cancer has not been successful regardless of numerous studies, which suggests that 
ovarian cancer develops de novo (Kurman and Shih Ie 2010). The origin of an ovarian tumor is 
still under debate. It was believed that ovarian cancer originates from the ovarian epithelium and 
different progenitor cell types resulting from metaplastic changes (Kurman and Shih Ie 2010). 
This understanding has been challenged in recent years, suggesting that the ovarian cancer is 
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derived from Mullerian-type tissue and not from the ovarian surface epithelium (Kurman and 
Shih Ie 2010). 
It is not surprising that ovarian cancer is a compound disease due to its structures. The 
ovary is a complex organ and composed of various cell types for specific functions to support 
structure, hormone production, and reproduction. Ovarian cancer can be generally categorized 
into three main different types: sex cord-stromal tumors, germ cell tumors, and epithelial ovarian 
cancer (George, Garcia, and Slomovitz 2016). Epithelial ovarian cancer accounts for more than 
90% of all ovarian cancer cases, while germ cell and sex cord-stromal ovarian cancer account for 
3% and 2% of cases respectively (Figure 1.1.1) (Siegel, Miller, and Jemal 2018). Germ cell 
ovarian cancers originate from the germ cells of the ovary. The origin of sex cord-stromal 
ovarian cancers is from the other supportive cells in the ovarian follicles. The origin of epithelial 
ovarian cancer is unresolved and an issue of a longstanding debate. 
Epithelial ovarian cancer (EOC) can be delineated into different histologic subtypes: 
mucinous (6%), endometrioid (10%), clear cell (6%), and serous carcinoma (52%) (Erickson, 
Conner, and Landen 2013). The serous tumors are thought to originate from the epithelial cells 
of the fallopian tube and later migrate to the ovaries (Siegel, Miller, and Jemal 2018). The 
endometrioid and clear cell tumors originate in the endometrium. Mucinous tumors are from the 
fallopian tube-peritoneal junction or the ovaries (Siegel, Miller, and Jemal 2018). The serous 
carcinoma can be further divided into (1) high-grade or (2) low-grade serous carcinoma. 
Based on morphologic, immunohistochemical, and molecular genetic studies, epithelial 
ovarian cancer can be categorized into type I or type II ovarian cancer (Kurman and Shih Ie 
2011). Type I tumors present at a low stage, and the disease progresses in a stepwise manner 
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(Jones et al. 2012). Type I tumors that are confined to the ovary have a good prognosis, although 
advanced stage type I tumors have a poor outcome (Kurman and Shih Ie 2016). Type I ovarian 
tumors are divided into three groups: endometriosis-related tumors, low-grade serous 
carcinomas, mucinous carcinomas and malignant Brenner tumors (Kurman and Shih Ie 2016). 
Type I endometriosis-related tumors include endometrioid, clear cell, and seromucinous 
carcinomas (Kurman and Shih Ie 2016). Genetic mutations such as KRAS, BRAF, PTEN, 
PIK3CA, ERBB2, ARID1A, and CTNNB1 are common in type I ovarian cancers, but TP53 
mutations are very rare (Kurman and Shih Ie 2011). Type II ovarian tumors are normally high-
grade serous carcinoma, high-grade endometrioid carcinoma, malignant mixed mesodermal 
tumors, and undifferentiated carcinomas. Type II ovarian cancers are highly aggressive and 
normally present in advanced stages. A typical “tubal intraepithelial carcinoma” (TIC) and 
“serous tubal intraepithelial carcinoma” (STIC) are observed in ovarian high-grade serous 
carcinomas in both women with inherited BRCA1 or BRCA2 mutations and women without a 
known predisposing genetic mutation for ovarian cancer (Kurman and Shih Ie 2016). Type II 
ovarian cancers harbor TP53 mutations in almost all tumors according to The Cancer Genome 
Atlas (TCGA) project of ovarian cancer (Kurman and Shih Ie 2016). In addition, DNA copy 
number gains or losses in CCNE1, NOTCH3, AKT2, RSF1, and PIK3CA are other molecular 
features of type II high grade serous ovarian cancer (Kurman and Shih Ie 2011).  The term “p53 
signatures” is used to describe the high-intensity immunostaining for p53 in STICs and TP53 
mutations are associated with the p53 signatures in some STICs (Kurman and Shih Ie 2011). 
The main reason to analyze epithelial ovarian cancers into type I and type II groups is the 
relation of the different histologic subtypes to precursor lesions (Kurman and Shih Ie 2016). In 
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type I epithelial ovarian cancers developed from well-established benign precursor lesions of 
borderline or atypical proliferative tumors (Kurman and Shih Ie 2016). There is no precursor 
lesion in type II epithelial ovarian cancers and considered as de novo development (Kurman and 
Shih Ie 2016). The studies have shown that type II carcinomas develop from an intraepithelial 
carcinoma in the fallopian tube, located in the fimbria and designated as STIC in the past few 
years (Kurman and Shih Ie 2016). 
 
Figure 1.1.1. Percent distribution of different ovarian cancer cases by subtypes. The pie chart 
represents the distribution of ovarian cancer cases by subtypes in the United States. Other or unspecified 
subtype includes very low occurring ovarian tumors as well as tumors that are hard to categorize based 
on the histological phenotype. Source: North American Association of Central Cancer Registries 
(NAACCR), 2017. 
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1.1.1: Ovarian cancer stages 
As with other cancers, the outcome of ovarian cancer in patients is dependent upon the 
stage of disease at the time of diagnosis. International Federation of Gynecology and Obstetrics 
(FIGO) staging system is a standardized method for the staging of ovarian tumors once the 
patient is diagnosed with the disease (Prat 2015). The additional discovery of high-grade serous 
tubal intraepithelial carcinoma (STIC) along with different tumor histopathological tissues is 
expected to modify the stages of ovarian cancer (Prat 2015). According to the new updated 
staging system of ovarian cancer, the stages of ovarian cancer are as follows:  
Stage I – Tumor is confined only to either ovaries or fallopian tubes. 
Stage II – Tumor involves either one or both ovaries or fallopian tubes with a pelvic 
extension or primary peritoneal cancer. 
Stage III – Tumor involves either one or both ovaries or fallopian tubes, or primary 
peritoneal cancer, with cytologically or histologically confirmed spread to the peritoneum 
outside the pelvis and/or metastasis to the retroperitoneal lymph nodes. 
Stage IV – Tumor is metastasized to distant organs excluding peritoneal metastases. 
 
1.1.2: Ovarian cancer symptoms 
Common symptoms of ovarian cancer are often mistaken with digestive disease and 
include abdominal bloating, indigestion, nausea, increased abdominal girth, tiredness and loss of 
appetite. Those whispering symptoms have made the diagnosis of ovarian cancer challenging 
and frequently misread as indigestion by patients. If the patient is suspected with the disease, 
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physical examination along with blood tests and imaging computed tomography (CT) scan or 
magnetic resonance imaging (MRI) are part of the tools for diagnosing ovarian cancer (Siegel, 
Miller, and Jemal 2018).  The two most commonly used screening methods in ovarian cancer are 
a transvaginal ultrasound and the cancer antigen 125 (CA125) blood test. The CA125 levels 
often drop with decreased ovarian tumor mass, and it surrogate biomarker to monitor disease 
progression after treatment rather than the diagnostic test for ovarian cancer. Although a 
transvaginal ultrasound and the CA125 blood tests are extensively used in clinics to detect 
ovarian cancers in women, the methods are not reliable to detect early disease in patients. 
Randomized clinical trials assessing the efficacy of cancer antigen CA125 and transvaginal 
ultrasound on ovarian cancer mortality demonstrated that there was no difference between 
control and test groups (Buys et al. 2011) (Skates et al. 2017). The control group did not receive 
annual screening such as CA125 blood test and transvaginal ultrasound, while the test group 
received the annual screening for ovarian cancer (Buys et al. 2011). 
 
1.1.3: Ovarian Cancer treatment 
The standard treatment procedures for patients with advanced ovarian cancer are as 
follows: 
1. Optimal debulking surgery: The surgery procedure to remove all tumors larger than 1 cm 
(Altman et al., 2012). This includes removing the uterus (hysterectomy) or both ovaries 
and fallopian tubes (bilateral salpingo-oophorectomy) if the pathology test is positive for 
the presence of a tumor.  
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2. Chemotherapy: Chemotherapy given for ovarian cancer is generally a combination of 
platinum- or taxane-based drugs administered intravenously based on the recommended 
dose by the oncologist. Currently, the standard chemotherapy regimen includes a 
platinum compound such as cisplatin or carboplatin and a taxane agent such as paclitaxel 
or docetaxel (Akin et al., 2014; Sharma et al., 2009).    
3. Targeted therapy: Targeted therapy is a promising strategy to treat ovarian cancer patients 
because there is little or almost no damage to normal cells. The targeted therapies are 
either drugs or other agents that attack cancer cells only. There are limited FDA-approved 
target therapies and clinical trials of specific targeted therapies in ovarian cancer in recent 
years. The examples of these targeted therapies are the angiogenesis inhibitor 
bevacizumab (McClung and Wenham, 2016; Pujade-Lauraine et al., 2014) and PARP 
inhibitors olaparib, rucaparib, and niraparib (Bamford and Webster, 2017) (Mirza et al. 
2016) for patients with hereditary BRCA mutations or somatic BRCA mutations. 
Tazoparaib and Veliparib are other PARP inhibitors and testing in early clinical trial 
(Mittica et al. 2018).  Clinical trials are on the way to investigate the effectiveness of 
combination treatment with these agents together with standard chemotherapy and 
immunotherapies or maintenance therapy or monotherapy in a wide range of settings in 
ovarian cancer (Mittica et al. 2018) (Mirza et al. 2016).  
The National Cancer Institute (NCI) defined ovarian cancer as cancer that is formed in 
the tissues of the ovary. The multiple studies of ovarian cancer have demonstrated that ovarian 
cancer is a heterogeneous disease with different origins (Levanon, Crum, and Drapkin 2008). 
Molecular genetic studies have revealed that the origin of ovarian cancer is not primarily in the 
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ovaries, and more than one test is required to detect all different types of ovarian carcinomas 
(Kurman and Shih Ie 2011). The current treatment for ovarian cancer mainly depends on the 
stage of cancer, tumor characteristics, and subtype (Siegel, Miller, and Jemal 2018). Based on 
the recent literature, treatment for ovarian cancer should be modified in every patient according 
to the molecular mutations, pathway inactivation of the patient’s tumor type and sub-type of the 
disease (Kurman and Shih Ie 2011).  
 
1.2 The guardian of the genome: p53 protein 
The different studies of TP53 have led to identifying the encoded protein as a tumor 
antigen, an oncogene or a tumor suppressor (Levine, Momand, and Finlay 1991). The TP53 gene 
was first discovered in the transformed cells interacting with antiserum from animals with 
tumors induced by simian virus 40 (SV40) (Levine, Momand, and Finlay 1991). The TP53 was 
found in the transformed cells together with large T-antigen, which was required for the 
transformed phenotype, and was identified as an oncogene. The initial TP53 cDNA clones used 
in these studies were the mutant forms of the gene, and a later cloning and characterization of the 
wild-type TP53 firmly established its role in suppressing the growth of transformed cells 
(Levine, Momand, and Finlay 1991). As a result, wild-type TP53 is now characterized as a tumor 
suppressor due to its ability to suppress oncogenic activities (Oren 1999). The TP53 tumor 
suppressor gene encodes the p53 protein, and p53 plays a critical role in maintaining the integrity 
of the genome by controlling the cell cycle and cell death to prevent tumorigenesis in normal 
cells (Vogelstein, Lane, and Levine 2000). The p53 protein responds to the various stress signals 
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in cells, including DNA damage that can lead to replication stress, hypoxia, nutrient deprivation, 
ribosomal stress, and oncogenic activations.   
 
Figure 1.2.1. Schematic diagram of p53 protein structure. The p53 protein is 53kDa and has four 
functional structure domains. The N-terminal domain contains a transcriptional activation domain and 
Proline-rich domain.  The central domain is where sequence-specific binding with the target genes and 
the other proteins can bind p53 at the C-terminal domain for regulation of genes in its network.   
 
The human TP53 gene is approximately 20 kb long and is located on the short arm of 
chromosome 17. The TP53 gene has 11 exons and the gene has maintained highly conserved 
sequences throughout its evolution (Soussi et al. 1987). The p53 protein is export from the 
cytoplasm to the nucleus where it forms a dimer of dimer and becomes an active transcription 
factor. The human p53 protein has 393 amino acids and contains four functional domains 
(Levine 1997). The four functional domains are (1) transcriptional activation domain, (2) 
proline-rich domain, (3) sequence-specific DNA binding domain in the center and (4) 
oligomerization and regulatory domains at the C-terminus. 
The transcriptional activation domain is at the N-terminus, and it is required for 
interacting with basal transcriptional machinery to regulate genes expression in normal cells 
(Levine 1997).  For example, the p53 amino acids F19, L22 and W23 are required for binding of 
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TATA-associated factors (Thut et al. 1995), and the p53 amino acid residues 22 and 23 are 
required for the binding of Mdm2 protein (Levine 1997). The N-terminal domain of p53 protein 
has binding sites for both positive and negative regulation of p53-dependent transcriptional 
activities (Levine 1997). The regulations of p53 are mainly through post-translational 
modifications and some of those modifications are at the N-terminal of the protein. 
Phosphorylation of p53 at the S46 position is required to induce the pro-apoptotic gene AIP-1 
after UV treatment in vivo (Oda et al. 2000). AMPK (Okoshi et al. 2008) and DYRK-2 (Taira et 
al. 2007) can bind to p53 at the same position of S46 amino acid residue and activate genes that 
are involved in cell death. In addition, the nuclear localization signal of the p53 protein is located 
in the N-terminal domain. 
The DNA binding domain of p53 protein interacts with DNA in a sequence-specific 
manner, and the mutations in this domain can disrupt the binding of the p53 protein to its target 
genes (Levine 1997) (May and May 1999). The majority of cancer-associated mutations in TP53 
are point mutations that lead to a single amino acid substitution in the DNA binding domain 
(Vousden and Lu 2002) and these types of mutations are called missense mutations. 
Furthermore, the mutations in DNA binding domain can divide into two classes: (1) mutations 
that directly interfere with the sequence-specific DNA binding (so called “contact mutants”) and 
(2) mutations that lead to conformational changes of p53 protein (so called “conformational 
mutants”)  (Levine 1997). Unlike mutations in other genes, the DNA contact mutations of TP53 
can sometimes retain the mutant/wild-type p53 complexes and can interfere with wild-type p53 
functions. Structural mutations change the p53 protein conformation, and the mutated p53 
protein can then bind to other proteins which are not observed with the wild-type p53. The DNA 
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binding domain of p53 recognizes and binds to a consensus target sequence (el-Deiry et al. 
1992). The central domain of p53 also interacts with other proteins such as 53BP1 and 53BP2 
(Ruppert and Stillman 1993) and functions as the protein bind domain for the p53 protein. 
The oligomerization domain (amino acid residues 324-355) of the p53 protein is required 
for the tetramerization in normal cells. The formation of a dimer of a dimer protein structure is 
necessary to regulate the ability of p53 to assist the binding of specific DNA sequences at its 
core domain (Levine 1997). The C-terminal domain of p53 is subjected to the post-translational 
modifications and interacts with other regulatory proteins to maintain genomic stability in 
normal cells (Levine 1997). 
The p53 protein is not required for the normal functions of cells within the body as 
evidenced by the p53 knockout mice having normal development and maturation processes 
(Oren 1999). The broad range of stress that leads to genomic instability is the key to 
carcinogenic mechanisms and those events will trigger the activation of p53 in cells (Oren 1999). 
The activation of p53 happens in three steps: (1) the stabilization and accumulation of p53 in the 
cell; (2)  sequence-specific DNA binding to target genes; and (3) target gene activation in 
response to the stress in the normal cells (Kruse and Gu 2009). From the functional aspect, p53 
protein is the transcription factor that can regulate the expression of genes involved in cell cycle 
and growth arrest or cell death. The N-terminal transcription activation domain and a DNA 
sequence-specific DNA binding domain are required for the p53 transcriptional activities (Chen, 
Lin, and Levine 1995). The first step of p53-mediated activation in target genes is binding of the 
protein to the specific sequence in DNA, and it is not surprising that the majority of p53 
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missense mutations are located in the DNA binding domain of the protein (Beckerman and 
Prives 2010). 
 
1.3 The negative regulator of p53: Mdm2  
The MDM2 (murine double minute 2) gene is approximately 42 kb long and has eleven 
coding exons. There are two different promoters for the MDM2 gene leading to the different 
transcripts (Barak et al. 1994). The largest human MDM2 protein consists of 491 amino acids 
and contains domains conserved among species from human to zebrafish (Marechal et al. 1997). 
The conserved region at the N-terminal domain of the MDM2 interacts with p53 and inhibits the 
p53 transcriptional activation functions (Chen, Marechal, and Levine 1993). Another conserved 
nuclear localization sequence (NLS) and nuclear export signal sequence (NES) facilitate the 
proper nuclear-cytoplasmic trafficking of the MDM2 protein (Roth et al. 1998). Those signals 
are required and essential for the Mdm2 to regulate p53 protein levels in cells (Roth et al. 1998). 
The conserved region at the C-terminal domain of MDM2 has the caspase 3 cleavage site (Chen 
et al. 1997) and three putative DNA protein kinase (DNA-PK) phosphorylation sites (Marechal 
et al. 1997). The two conserved zinc fingers region in the C-terminal RING (Really Interesting 
New Gene) domain are required for the binding of zinc molecules and the proper folding of the 
RING domain. The conserved regions in the RING domain bind to a specific RNA sequence and 
probably play a role in the regulation of p53 (Honda, Tanaka, and Yasuda 1997). The amino acid 
residues G58, V75, D68 and C77 on the Mdm2 protein are critical for binding to p53 protein, 
and the mutation in those amino residues could result in the disruption of interaction between 
MDM2 and p53 (Kussie et al. 1996). 
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Figure 1.3.1.  Schematic diagram of MDM2 protein structure. MDM2 interacts with p53 at N-terminal 
and p53 DNA binding domain located between the acidic domain and Zn domain. There are Nuclear 
Localization Signal (NLS) and Nuclear Export Signal (NES) to transport MDM2 protein from cytoplasm 
to nucleus and vice visa. The Zn and RING domains of MDM2 interact with other proteins. 
 
  MDM2 inhibits p53’s transcriptional functions by several different mechanisms. First, 
MDM2 blocks the transcriptional activities of p53 by competing with TFIID transcription factor 
complex and leads to transcriptional suppression of the downstream target genes in the p53 
pathway. The binding of MDM2 to p53 leads to a decrease in the activation of p53-responsive 
reporter genes in both mammalian cells and in yeast (Chen, Lin, and Levine 1995). The 
transcriptional activities of p53 in the absence of MDM2 can be explained in the MDM2 
knockout mice model. MDM2 homozygous knockout mice are embryonically lethal, and the 
lethality phenotype can be rescued by the additional homozygous deletion of p53 gene. The 
transcriptional activities of p53 in the absence of regulation of MDM2 results in embryonic 
lethality in the knock out mice model (Jones et al. 1995) (Montes de Oca Luna, Wagner, and 
Lozano 1995). Second, MDM2 can regulate the endogenous p53 protein level in both the wild-
type and heterozygous mutant (Haupt et al. 1997) (Kubbutat, Jones, and Vousden 1997). The 
decrease in endogenous p53 levels is not dependent upon the transcription of p53 genes or 
mRNA, but the ability of MDM2 to transport p53 protein from the nucleus to the cytoplasm for 
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ubiquitinated degradation (Roth et al. 1998). MDM2 is an E3 ubiquitin ligase that binds to the 
p53 protein to target for proteasomal degradation in the cytoplasm (Honda, Tanaka, and Yasuda 
1997). By targeting p53 for degradation, MDM2 effectively inhibits all activities of p53 in cells. 
For example, MDM2 inhibits p53-mediated transcriptional activation but does not prevent 
transcription-independent function of p53, such as an enhancement of DNA repair or the 
induction of apoptosis. To inhibit all p53 transcription-dependent and -independent activities of 
p53, including base-excision repair (BER), DNA double-strand exonuclease activity, and p53-
mediated cell death, the proteasomal degradation of p53 by MDM2 is the most effective method 
to inhibit all p53 activities (Honda, Tanaka, and Yasuda 1997) (Roth et al. 1998). 
 
1.4 The p53-MDM2 autoregulatory feedback loop 
In normal and non-malignant cells, the level of p53 is very low due to the protein’s short 
half-life regulated by MDM2. The p53 protein transactivates MDM2 transcription and MDM2 in 
turn ubiquitinates p53 and facilitates the degradation of p53. This autoregulatory negative 
feedback loop controls the basal level of both p53 and MDM2 proteins. In normal cells, 
maintenance of autoregulatory feedback is necessary to overcome the inhibition of p53 by 
MDM2 under certain circumstances. One of the mechanisms to regulate the autoregulatory 
feedback loop is to lower Mdm2 protein level. Another mechanism is to block the interaction of 
p53 and MDM2 by blocking with the small molecule inhibitor to activate p53 transcriptional 
activities. 
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Figure 1.4.1. The negative autoregulatory feedback loop. p53 regulates MDM2 expression by binding to 
its promoter. The MDM2, in turn, suppresses p53 by directly binding transcriptional activities, by binding 
at the p53 transactivational domain and by targeting p53 for proteasomal degradation. The 
autoregulatory feedback loop helps to keep low p53 protein level in normal cells.   
 
 
The MDM2 gene is either over-expressed or amplified in a significant number of human 
cancers (Momand et al., 1998). MDM2 is one of p53’s transcriptional targets, and it is activated 
by p53 as the autoregulatory loop (Bond et al. 2005). Under normal physiological conditions, the 
p53 level is regulated by the MDM2 protein. In turn, the MDM2 protein directly binds to the N-
terminal of the p53 protein and is targeted for protein degradation (Jones et al. 1995). It is not 
surprising that the MDM2 gene is either over-expressed or amplified in a significant number of 
human cancers (Momand et al., 1998). 
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1.5 Small molecule inhibitor – Nutlin3a  
 
Figure 1.5.1.  The chemical structure of Nutlin-3a (Source PubChem) 
 
 The crystal structure of MDM2 bound to the peptide of p53 transactivation domain 
revealed that MDM2 possesses a hydrophobic pocket (Vassilev et al. 2004). The presence of the 
pocket on the Mdm2 protein provided the hypothesis that compounds with low molecular weight 
could fit in the pocket to block the interaction of MDM2 with p53. A diverse library of synthetic 
chemicals was used to identify compounds for the pocket of MDM2 (Vassilev et al. 2004). The 
Nutley inhibitor (Nutlins) compound disturbed the binding of the recombinant p53 protein with 
MDM2 with inhibitory concentration (IC50) values in the 100-300 nM range (Vassilev et al. 
2004). The crystal structure of human MDM2-Nutlin2 complex confirmed that the inhibitor 
binds to the p53 binding site on MDM2 to a high degree, occupying all three binding pockets of 
MDM2 (Vassilev et al. 2004). Nutlin-3a has the potent binding activity and IC50 of 0.09 µM in 
comparison with the rest of its analogues (Vassilev et al. 2004). According to the model for p53 
regulation by MDM2, treating cells with the inhibitor (Nutlin compound) resulted in (1) 
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stabilization and accumulation of p53 protein due to MDM2 inability to export p53 protein from 
nucleus to cytoplasm for protein degradation, (2) transactivation of MDM2 expression and (3) 
activation of p53 transcriptional activities (Vassilev et al. 2004). These molecular events in turn 
contribute to cell cycle arrest, apoptosis or both in cells with wild-type p53 (Vassilev et al. 
2004). The wild-type p53 level increases in cells treated with the Nutlin compound as well as the 
level of MDM2 and p21, which is consistent with the activation of the p53 pathway (Vassilev et 
al. 2004). Nutlin-3, arbitrarily called enantiomer-a (Nutlin-3a), was used in many of the 
experiments as part of this thesis because it possesses potent binding activity in comparison with 
other enantiomers. 
 
1.6 Forward genetic screening using a small molecule inhibitor 
 We employed a similar experimental approach that was originally used to identify RAS 
oncogene from a phage library. In the original approach that identified RAS oncogene from a 
phage library, DNA from human tumor cells was used to transfect mouse 3T3 cells and cultured 
for two weeks. The transformed cells were observed, and the DNA was extracted from those 
transformed cells to transfect mouse 3T3 cells for the second time. After the second round of 
transfection and the selection of the transformed phenotype, the phage library was constructed 
from the extracted DNA of the transformed 3T3 cells. By using a human-specific Alu probe, the 
phage library was screen for bacteriophages carrying human DNA. This forward genetic 
screening approach resulted in the identification of RAS oncogene (Parada et al. 1982) 
(PMID:6283357). We used similar approach with minor modification to identify candidate genes 
that negatively regulate wild-type p53 function. We used total RNA isolated from twelve 
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individual ovarian tumor tissue samples to create a pooled tumor-derived cDNA library. The 
pooled patient-derived cDNA library was transduced into A2780 ovarian cancer cells with wild-
type p53. Using Nutlin-3a resistance as a phenotypic screening tool, we identified the candidate 
exogenous negative effectors of p53 in these cells. The resistance to Nutlin-3a conferred by 
exogenously transduced genes from the library suggests these candidate genes produce negative 
effects on p53 activities related to apoptosis and cell cycle arrest. 
 
 
Figure 1.6.1. The concept of a forward genetic screening.  If there are surviving cells after the Nutlin-3a 
selection, those cells will have the exogenous effector or effectors that are negatively regulating the wild-
type p53 protein functions.    
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1.7 Specific aim 
 The primary goal of this thesis is to identify negative regulators of p53 function in 
ovarian cancers and to have a better understanding of p53-dependent transcriptional activities in 
ovarian cancer patients with wild-type TP53. 












Chapter 2:  Materials and Methods 
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2.1 The patient-derived pRetro-LIB cDNA library  
The pRetro-LIB patient-derived cDNA library was constructed using in a total of twelve 
carcinoma samples from patients with ovarian cancer. These tumor samples were collected and 
used in accordance with approved protocol by the institutional review board of the Mayo Clinic. 
Most of the patients had primary advanced stage disease, while three recurrent tumor samples 
were also included in the total of 12 ovarian tumors. Ten out of 12 patients had the treatment-free 
interval (TFI) less than 6 months and were considered to have the chemotherapy-resistant 
disease. The TFI for two patients were not known. The tumors consist of the following subtypes 
of ovarian cancer: nine high-grade serous, two clear cell, and one endometrioid. Using Trizol 
RNA purification methods, the total RNA was extracted from nine primary and three recurrent 
ovarian tumors. The total RNA (2 µg) from each tumor sample was pooled together to generate a 
custom patient-derived retroviral cDNA library. The library was generated using a contract 
service from the Clontech Laboratories (Mountain View, CA). 
 
2.2 Cell lines and cell culture 
Human ovarian cancer cell line, A2780, was provided by Dr. Andrew Godwin (the 
University of Kansas Medical Center). A2780 cells are TP53 wild-type and based on molecular 
profiling are speculated to be of clear cell origin (Domcke et al. 2013). Cancer cells were 
cultured in the media 1:1 mixture of M-199/MCDB-105 (catalog # M4530 and M6395) from 
Sigma-Aldrich (St. Louis, MO, USA) supplemented with 5% fetal bovine serum (catalog # 
F8067) from Sigma-Aldrich (St. Louis, MO, USA), and 1% penicillin and streptomycin (catalog 
# K952) from VWR (Radnor, PA, USA). The Phoenix-AMPHO cell line (catalog # STCC CRL-
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3213) was purchased from ATCC. The Phoenix-AMPHO cells were maintained in high glucose 
Dulbecco’s modified Eagle’s medium (DMEM) media (catalog # D5796) from Sigma-Aldrich 
(St. Louis, MO, USA), supplemented with 10% fetal bovine serum (catalog # F8067) from 
Sigma-Aldrich (St. Louis, MO, USA) and 1% penicillin and streptomycin (catalog # K952) from 
VWR (Radnor, PA, USA) according to ATCC recommendation. All cells were maintained in a 
humidified atmosphere at 37°C with 5% CO2/air atmosphere and passaged using 0.25% 
trypsin/EDTA (catalog # T4049) from Sigma-Aldrich (St. Louis, MO, USA). 
 
2.3 Retroviral production  
The helper plasmids VSV-G and gag-pol were used together with the patient-derived 
cDNA plasmid library to transfect Phoenix –AMPHO cells (catalog # ATCC CRL-3213) from 
ATCC (Manassas, VA, USA) for retroviral particles. Transfection was performed using the 
Lipofectamine LTX with PLUS reagent (catalog #15338030) from Invitrogen (Waltham, MA, 
USA) in OPTI-MEM media (catalog #11-058-021) from Invitrogen (Waltham, MA, USA). The 
empty plasmid was used as the control for transfecting Phoenix-AMPHO cells. After 5 hours 
post-transfection, the regular media was added into cells to a total volume of 10 mL. The 
transfected cells were cultured in a humidified atmosphere at 37°C with 5% CO2/air atmosphere, 
and retroviral particles were harvested after 48 hours and 72 hours post-transfection. The 
collected retroviral particles were centrifuged at 2,000 rpm at 4°C for 10 min to remove the cell 
pellet. The supernatant was filtered through a syringe filter using 0.45 µM low protein binding 
membrane (Millipore steriflip HV/PVDF) to remove any trace of cell debris. After taking out the 
required amount of retroviral particle for titration with the kit, the rest of the aliquots were stored 
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at -80°C until future usage. The retroviral titer was determined by using Retro-X qRT-PCR 
Titration Kit (catalog# 631453) from Takara Bio USA (Mountain View, CA, USA) so that 
multiplicity of infection (MOI) of 1 could be calculated from the retroviral titer concentration. 
The filter retroviral particles were transduced into the ovarian cancer cells A2780 after the 
retroviral titer was determined by qRT-PCR Titration kit.   
 
 2.4 pRetro-cDNA library screening 
Ten million A2780 cells were transduced with retroviral particles at a multiplicity of 
infection (MOI) of 1 in the media containing the infection reagent polybrene (4 µg/ml) (catalog 
#H9268) from Sigma-Aldrich (St. Louis, MO, USA). Nutlin-3a (40 µM) (catalog# S8059) from 
Selleckchem (Houston, TX, USA) was added to the A2780 cells after 24 hours of post-infection 
with retroviral particles. Nutlin-3a was added every 48 hours for three times with fresh media 
after washing with phosphate-buffered saline (PBS). The retroviral particles with empty plasmids 
were used as the control in A2780 cells during the library screening experiment. The surviving 
clones were picked up individually and transferred to one clone per well into 24-well plates. 
Those cells were re-plated into two 35-mm dishes, and the first well of the cell was used to 
extract gDNA to perform the pRetro-specific PCR to identify the potential candidate genes from 
the screen. The second well of the cells was kept for the culture for future experiments. 
 
2.5 Genomic DNA (gDNA) extraction  
 The 5 x 106 cells were harvested by using trypsin treatment and the cell pellet from 
pRetro-cDNA-infected A2780 cells was collected. The cell pellet was washed twice with 1X 
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PBS and re-suspended in 500 µL of 1x PBS solution. The cell pellet was digested with protease 
K solutions, lysed cells and extracted genomic DNA according to the manufacturer protocol. The 
Blood & Cell Culture DNA Mini Kit (catalog # 13323) from Qiagen (Germantown, MD, USA) 
was used to extract the genomic DNA of pRetro cDNA transfected A2780 cells.  
 
2.6 pRetro-LIB-specific PCR  
 The PCR reaction was performed using the patient-derived pool cDNA library specific 
primers called pRetro-LIB primers. Amplification was performed in 50 µL reaction volume and 
consisting of 10.0 µL nuclease-free water, 2.50µL forward primer (300 nM), 5.0 µL reverse 
primer (300 nM), 5.0 µL of Expand High Fidelity buffer (5X), 1.0 µL of template (250 ng), 0.75 
µL of Expand Long Taq polymerase mix (catalog # 04 738 268 001) from Roche (Indianapolis, 
IN, USA) and 1.0 µL of dNTP mix (200 µM). PCR was performed using the Bio-Rad T100 
Thermal Cycler machine. The thermal cycle was programmed for 2 minutes at 94°C for initial 
denaturation, 10 cycles of PCR reaction with each cycle constituting 30 seconds at 94°C for 
denaturation, 30 seconds at 56.5°C for annealing, 8 minutes at 68°C for extension, and followed 
by an additional 25 cycles of PCR reaction with each cycle constituting 30 seconds at 94°C, 30 
seconds at 56.5°C, 8 minutes with 20 second increment per cycle at 68°C and 10 minutes at 68°C 
for final extension. PCR products were examined by electrophoresis at 180V for 30 minutes in a 
1% (w/v) agarose gel in 1X TAE buffer. The 1kb DNA ladder (catalog # N3232L) from New 
England Biolabs (Ipswich, MA, USA) was used as the marker. The EZ-Vision One (catalog # 
97064-192) from VWR (Radnor, PA, USA) was added into electrophoresis gel solution for 
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visualization of the PCR products. The PCR products were visualized and documented using the 
ChemiDoc TM MP Imaging System (BioRad). The primer sequences are listed in Table 2.6.1.  
 
Table 2.6.1. Lists of primer sequences used in pRetro-LIB specific PCR reaction.  
  
2.7 Antibodies and compound 
Mouse monoclonal anti-NIFK (18E148) antibody (catalog # sc-52904) and mouse 
monoclonal anti-p53 (DO1) antibody (catalog# sc-126) were purchased from Santa Cruz 
Biotechnology (Sant Cruz, CA, USA). Mouse monoclonal anti-NIFK (18E148) antibody 
(catalog # GTX13880) was purchased from GeneTex (Irvine, CA, USA). Mouse monoclonal 
anti-NIFK (CL2240) antibody (catalog # ab211871) was purchased from Abcam (Cambridge, 
MA, USA). Mouse monoclonal anti-beta-actin antibody (catalog# A1978) was purchased from 
Sigma-Aldrich (St. Louis, MO, USA). For secondary antibodies, anti-mouse IgG-HRP antibody 
(catalog # sc-2371) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). 
Nutlin-3a (catalog# S8059) was purchased from Selleckchem (TX, USA). Nutlin-3a solutions 
were dissolved in DMSO (catalog #) at 100mM and stored at -80°C. 
 
2.8 Immunoblotting 
 Cells were scraped and centrifuged at 1,000 xg for 5 minutes to get the cell pellets. The 
cell pellets were washed with 1X ice-cold PBS solution twice and lysed in 2X Laemmli sample 
Primer Name Forward Sequence Reverse Sequence
pRetro-LIB 5'-AGCCCTCACTCCTTCTCTAG-3' 5'-ACCTACAGGTGGGGTCTTTCATTCCC-3'
PCR
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buffer (catalog # 161-0737) from Bio-Rad Laboratories (CA, USA) with 5% β-mercaptoethanol 
(catalog # M3148-100mL) from Sigma-Aldrich (St. Louis, MO, USA). The cell lysates were 
boiled at -95°C for 5 minutes before being loading into SDS polyacrylamide gel. 
 
2.9 Real-time quantitative PCR (RT-qPCR) 
 The total RNA was extracted with the Trizol reagent (catalog # 15-596-018) from 
Invitrogen (Waltham, MA, USA) according to the manufacturer’s protocol. One µg of total RNA 
was used for cDNA synthesis using SuperScript II reverse transcriptase (catalog # 18064-014) 
from Invitrogen (Waltham, MA, USA) according to the manufacturer’s protocol in a 20 µL 
reaction. The cDNA was diluted into 1:20 in nuclease-free water and 1 µL of diluted cDNA was 
used in the qPCR reaction with triplicates. The RT SYBR Green Flour qPCR Master Mix 
(catalog # 330513) from Qiagen (Germantown, MD, USA) was used in the reactions. The 
CFX384 Real-Time PCR Detection System (Bio-Rad) was used to perform the qPCR reactions. 
In addition, the non-template negative control was included in the qPCR reaction. The 18S rRNA 
was used as the amplification control to normalize the level of mRNA expression. The sequences 
of the primers were listed in Table 2.9.1.  
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Table 2.9.1. Lists of primer sequences used in quantitative reverse transcriptase polymerase chain 
reaction (qRT-PCR) 
 
2.10 siRNA transfection 
 A2780, A2780-NIFK, A2780-ΔKiFHA, A2708-ΔRRM and, A2780-T234/8-A cells were 
seeded in 6-well plates (0.35 x 106 cells per well).  Both control and MDM2 siRNA were 
purchased from IDT (Coralville, IA, USA).  Lipofectamine 2000 reagent (catalog # 11668-019) 
was purchased from Invitrogen (Carlsbad, CA, USA). The siRNAs and transfection reagent were 
added into the OPTI-MEM medium (catalog #51985091) from Invitrogen (Carlsbad, CA, USA) 
and incubated for 5 minutes at room temperature. The cells were washed with 1X PBS solution, 
and fresh Opti-MEM and siRNAs transfection mixture were added to the cells. Nutlin-3a (40 
µM) in M-199/105 media was added after 48 hours of post-transfection after the cells were 
washed with 1X PBS solution. After 24 hours later, cells were harvested and collected for the 
experiments.   
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2.11 Clonogenic assay 
 A2780, A2780-NIFK, A2780-ΔKiFHA, A2708-ΔRRM and, A2780-T234/8-A, 500 cells 
were seeded in 6-well plates to measure the proliferation. Cells were treated with different 
concentrations of Nutlin-3a (10 µM, 20 µM, 30 µM and 40 µM) and incubated for 72 hrs. The 
cells were washed with 1X PBS once before adding the fresh media after 3 days with Nutlin-3a 
treatment. The fresh media were added every 3 days after 1X PBS wash, and the colonies were 
allowed to form up to 14 days. At the end of the experiment, the cells were stained with Crystal 
Violet (catalog # C0775-110G, Sigma-Aldrich, St. Louis, MO, USA) Fixing/Staining solutions. 
  












Chapter 3: Results  
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3.1 Results 
3.1.1 Patient-derived cDNA library is used to identify negative regulators of the p53 pathway in 
ovarian cancer with wild-type p53 by a forward genetic screen. 
 To identify the potential negative regulators of the p53 pathway, we used Nutlin-3a as the 
tool to induce p53 pathway in ovarian cancer cells with wild-type p53. The total RNA from 12 
ovarian carcinoma samples was extracted, and the cDNA was generated using reverse 
transcriptase enzyme. The summary of tumor information is listed in Table 3.1.1. We also 
sequenced the selected tumor samples from the patient-derived pool cDNA library to make sure 
that the reference transcripts were present in our library using Next Generation Sequencing 
(NGS) technology from Illumina (Table 3.1.2). The data from the MiSeq sequencing of the 
cDNA library and GAII sequencing of the select tumor samples suggested a decrease in 
representation of novel transcripts and splice variants in the cDNA library. This decrease in 
presentation may be related to lower transcript coverage resulting from a reduced sequencing 








Table 3.1.1 Tumor types, histology, grade and stages of tumors in patient-derived cDNA library. Total 
RNA from individual patients’ tumors was extracted, pooled, and used to construct a retroviral-based 
cDNA library that was then transduced into A2780 cells.   
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Table 3.1.2 The patient-derived pool cDNA library and selected patients’ tumor samples were sequenced 
using Next Generation Sequencing by Illumina. The sequencing result proved that there were transcripts 
in both the library and tumor samples. 
 
3.1.2 Proof of concepts of screening procedure in target cells (A2780) 
 We performed the different infection methods to compare the transduction efficiency of 
retroviral cDNA library in A2780 cells. As a control, we used the pRetro-mCherry to visualize 
transduction efficiency in A2780 cells. We used 90% of the cDNA library and 10% of pRetro-
mCherry in Phoenix-AMPHO cells to produce the retroviral particles. We used two different cell 
lines, A2780 and NCI-H23, to transduce them with retroviral particles. From the results, the 
spin-fection method produced higher transduction rate in both cell lines (Figure 3.1.2). 
Therefore, we used the spin-fection methods in subsequent studies to transduce A2780 cells with 
the retroviral particles from the cDNA library. 
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To establish MOI for the infection experiment using the retroviral particles from the 
patient-derived cDNA library, we performed the qRT-PCR titration using the Retro-X qRT-PCR 
kit (catalog # 631453) from Clontech (Mountain View, CA, USA). We used the NucleoSpin 
RNA Virus Kit (catalog # 740956) from Clontech (Mountain View, CA, USA) to isolate viral 
RNA from the supernatant using the manufactory’s recommended methods. We followed the 
user manual without modification. The RNA copy number was tested with the filtered retroviral 
particles after 48 hours of post-infection to determine the multiplicity of infection (MOI) number 
for the infection experiment in the target cells. From the qRT-PCR result, the retroviral titer of 
the patient-derived cDNA library was 9.23 x108 copy/mL (Figure 3.1.1). 
  





Figure 3.1.1 The concentration of viral particles was determined using the Retro-X qRT-PCR kit. The 
viral particles were collected after 48 hours or 72 hours of post-infection and subjected to test for RNA 
copy number using Retro-X qRT-PCR Titration Kit. 
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We initially planned to use MOI of 1 for the infection experiment in A2780 cells. 
However, due to the very low transduction efficiency in A2780 cells, we ended up using MOI of 
2 for our infection experiment. From the results, the spin-fection method proved to have higher 
transduction rate in both cell lines (Figure 3.1.2). 
 
 
Figure 3.1.2 The proof of concept of the experimental methods and design. A2780 and NCI-H23 cells 
were transduced with retroviral particles of pool cDNA library together with 10% of retroviral particles 
of mCherry. The fluorescence signals from pRetro-mCherry were observed in the cells. 
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3.1.3 The different concentration of Nutlin-3a to be used in a forward genetic screen is tested. 
 We then tested the concentration of Nutlin-3a that is sufficient to suppress the clonogenic 
growth in A2780 cells. A2780 cells (cell number 5 x 106) were seeded in 150-mm tissue culture 
plate for overnight. The next day, different concentrations of Nutlin-3a (20, 40, 60, 80 and 100 
µM) were added to the fresh culture media every 24 hours up to three times. The media was 
discarded after 24 hours of the last treatment and washed with 1X PBS solution twice. The fresh 
regular culture media was added, and the cells were allowed to grow for another 14 days. The 
fresh media was added to the plates every 3 days after washing with 1X PBS solution. The result 
indicated that 40 µM Nutlin-3a was the best concentration to use in the screening experiment due 
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Figure 3.1.3 Nutlin-3a shows decreased in the survival of A2780 cells with increasing concentration. 
The ovarian cancer cells (A2780) were treated with different concentrations of Nutlin-3a ranging up to 
100 µM in 150-mm plates three times. The surviving cells were cultured for 14 days after the last dose of 
Nutlin-3a. The result indicated that 40 µM Nutlin-3a selection is appropriate for selection to limit false 
positives.   
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3.1.4 pRetro-LIB vector-specific PCR is used to identify the candidate negative regulators of the 
p53 pathway in the screening. 
 We used the vector-specific primers listed in Table 2.1.1 to rescue and identify 
exogenously transduced genes in surviving colonies after Nutlin-3a selection. We used the 
purified plasmid from the patient-derived pool cDNA library (henceforth referred to as pRetro-
LIB unless otherwise stated) as our positive control and genomic DNA of A2780 as our negative 
control in PCR reaction. Initially, we extracted genomic DNA from parental A2780 cells and 
from the cDNA library-infected cells, using the Blood & Cell Culture DNA Mini Kit (catalog 
#13323) from Qiagen (Germantown, MD, USA). The PCR reaction was performed using 
Expand High Fidelity PCR system (catalog # 04 738 250 001) from Roche (Indianapolis, IN, 
USA) in 50 µL reaction. The PCR products were run on 0.7% agarose gel to verify the product 
size. From the result on the agarose gel (Figure 3.1.4), we observed a similar smear pattern for 
all pRetro-LIB library including from A2780 cells infected with the patient-derived cDNA 
library. Only genomic DNA of A2780 cells did not have the smear pattern as expected. 
 
  




Figure 3.1.4 The PCR products of patient-derived cDNA library. Genomic DNA isolated from either 
parental A2780 and A2780 cells infected with patient-derived pool cDNA library were amplified by PCR 
using pRetro library specific primers and the produces run on an agarose gel. The positive control is the 
genomic DNA of pRetro-LIB plasmid and the negative control is genomic DNA of A2780 cells. The 
genomic DNA of Nutlin-3a produced clones were subjected to PCR and run on the agrose gel.  
 
3.1.5 Exogenous effector or effectors are identified from functional genetic screening. 
 The selection of the library-infected cells with 40 µM Nutlin-3a produced fifteen 
surviving colonies. We randomly picked up three colonies to extract genomic (gDNA) and 
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performed Sanger sequencing on the PCR products to identify potential candidate exogenous 
effectors.  The main reason to pick up only three colonies were due to the time limitation and the 
genomic (gDNA) from the rest of the colonies were extract for the future use.  The Sanger 
sequencing identified three candidate cDNAs, i.e., NIFK, GXYLT 1, and SACS, which encode 
for proteins that can putatively act as negative regulators of p53 function. Based on the 
sequencing results from four independent screening experiments, NIFK was the one candidate 
that showed up in all clones selected. NIFK is also known as Nucleolar Protein Interacting with 
the FHA Domain of MKI67 (MKI67IP) and nucleolar phosphoprotein (Nopp34). It is a putative 
RNA-binding protein and was discovered in the yeast two-hybrid screening using Ki-67 FHA 
domain as the bait (Takagi et al. 2001), and was also confirmed by directed proteomics analysis 
(Andersen et al. 2002).  NIFK protein interacts with Ki-67 through its FHA domain and the 
function of human NIFK protein in cancer is unknown (Li et al. 2004).  In general, NIFK protein 
consists of 293 amino acids and contains a N-terminal RNA recognition motif (RRM), a Ki-67 
FHA binding domain, and a lysine-rich domain (Li et al. 2004). Two phosphorylation sites, 
Thr234 and Thr238 of NIFK, were shown to be required for the interaction between NIFK and Ki-
67 FHA domain (Takagi et al. 2001). The binding between the Ki-67 FHA domain and NIFK 
appears to require a longer peptide fragment of 44 amino acid residues in vitro experiments (Li et 
al. 2004).    The RNA recognition motif (RRM) of NIFK protein is probably required for cell 
cycle progression and ribosome biogenesis (Lin et al. 2016).  The NIFK protein is known to 
localize mainly to nucleoli but has been detected in lower levels in the nucleoplasm and 
cytoplasm of cells. In previous studies, the nucleolar staining was reported to be reduced after 
the RNase A treatment prior to fixation in cells (Li et al. 2004) (Takagi et al. 2001).  




Figure 3.1.5.  Schematic diagram of NIFK protein structure. NIFK interacts with Ki-67 FHA domain and 
contains RNA recognition motif (RRM) and lysine-rich domain.   
 
3.1.6 NIFK overexpression in A2780 cells promotes resistance to Nutlin-3a in the proliferation 
assay.   
 Ki-67 is the nuclear protein that plays a role in cell proliferation, has high expression in 
diving cells in cell cycle, and is down-regulated in G0 quiescent cells (Gerdes et al. 1984) 
(Verheijen et al. 1989). It is typically a cellular marker for proliferation, but the mechanism of 
Ki-67 in cancer is not well studied. In addition, previous studies have shown that very low-level 
of Ki-67 can co-localized with the RNA polymerase I (Pol I) transcription machinery and can 
physically interact with the promoter region of the chromatin of rDNA (Bullwinkel et al. 2006). 
Ki-67 involvement in cell cycles with other protein is possibly through FHA domain and Ki-67 
FHA domain interacts with two novel proteins Hklp2 (human kinesin-like protein 2) and NIFK 
(human nucleolar protein interacting with the FHA domain of Ki-67) (Takagi et al. 2001) in a 
yeast two-hybrid screening. Thus, it is speculated that both proteins might play a role in signal 
transduction pathways in mammalian cells. 
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 To explore the potential role of NIFK in cancer, we introduced four different GFP-tagged 
NIFK expression plasmids (kindly provided by Dr.Tsung-Chieh Lin, Genomics Research Center, 
Academia Sinica, Taipei, Taiwan) into A2780 cells using retroviral particles to generate cells 
that exogenously overexpresses NIFK. GFP-tagged NIFK expression plasmids (1) full-length 
NIFK (2) ΔKi-FHA; FHA domain of NIFK protein is deleted (3) ΔRRM; RNA recognition motif 
of NIFK is deleted (4) T>A; two phosphorylation sites Thr234 and Thr238 mutated to Alanine 
were used to investigate the molecular function of NIFK protein in ovarian cancer (Li et al. 
2004).  The NIFK overexpressing A2780 cells (cell number = 500) were seeded in 6-well plates 
and incubated overnight. Different concentrations of Nutlin-3a (10, 20, and 30 µM) were added 
to the cells. Vehicle (DMSO) treated cells were used as the control. We observed differences in 
the number of colonies formed when comparing parental A2780 cells and NIFK overexpression 
cells (Figure 3.1.6 A & B) (Figure 3.1.6 C). The difference in colony formation between parental 
and NIFK overexpression cells was most obvious in cells treated with highest concentrations of 
Nutlin-3a (30 µM). 
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Figure 3.1.6(A & B) Colony Formation Assay. A2780 cells were used for the overexpression of NIFK, 
NIFK ∆Ki-FHA, NIFK ∆RRM and NIFK T>A. The NIFK overexpression cells and A2780 were plated in 
6-well tissue culture plate for colony formation assay. Colony formation of A2780 cells was inhibited 
more as the concentration of Nutlin-3a increased. The NIFK overexpression cells were still forming 
colony even in high concentrations of Nutlin-3a compared to the A2780 cell.  




Figure 3.1.6(C) Colony Formation Assay. The quantitation of colony formation of parental A2780 and 
cells overexpressing NIFK, NIFK ∆Ki-FHA, NIFK ∆RRM and NIFK T>A.  
 
 
We tested the level of exogenous NIFK expression by Westen blots in A2780 and NIFK 
overexpression cells. Cells were either treated with Nutlin-3a (30 µM) or DMSO as the control 
and incubated overnight. Cell lysates were collected and subjected to Western blot using NIFK 
monoclonal antibody. The exogenous NIFK protein levels in (1) full-length NIFK (2) ΔKi-FHA; 
FHA domain of NIFK protein is deleted (3) ΔRRM; RNA recognition motif of NIFK is deleted 
(4) T>A; two phosphorylation sites Thr234 and Thr238 were changed to Alanine and were 
elevated after Nutlin-3a treatment (40 µM) compared with A2780 and control (DMSO) cells 
(Figure 3.1.6 D).  We also tested other ovarian cancer cell lines for NIFK expression level and 
moderate to higher expressions were observed (data not included). To our surprise, the changes 
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treatment such as 10 µM concentration (data not showed).  Interestingly, the exogenous NIFK 
expression is upregulated after Nutlin-3a treatment compared with untreated control only in 
NIFK overexpression cells but not in A2780. One possible explanation for higher expression of 
exogenous NIFK in cells was due to differences in promoters. While endogenous promoter may 
be regulated by p53 and subjected to p53-mediated suppression, exogenous CMV promoter is 
not regulated by p53 in similar manner. The fact that exogenous NIFK expression is apparent 
only after endogenous NIFK expression was downregulated by Nutlin-3a suggests the levels of 
NIFK are tightly controlled in these cells. We also checked the expression of p53 and other 
proteins in its network such as p21, PUMA, and GADD45 (Figure 3.1.6 D). Consistent with the 
activation of p53 pathway by Nutlin-3a, we observed the induction of p21 and MDM2 and the 
suppression of c-Myc in Nutlin-3a-treated cells. PUMA expression is barely detectable in these 
cells and its expression is minimally increased in Nultin-3a-treated cells. The level of the growth 
arrest and DNA damage (GADD45) should have been induced upon Nutlin-3a treatment but the 
opposite effect was observed compare with untreated (DMSO) cells (Figure 3.1.6 D). However, 
GADD45 expression levels in A2780 and NIFK overexpression cells were almost the same in 
the Western blot regardless of treatment or control (Figure 3.1.6 D). Next, we examined the 
mRNA level of those genes by qRT-PCR to confirm that what we observed in protein level was 
also correlated with mRNA level (Figure 3.1.6 E). We observed that the mRNA expression of 
these target genes was increased by Nutlin-3a treatment compared with untreated (DMSO) 
(Figure 3.1.6 E). As expected, p53 could not regulate MDM2 transcription level upon Nutlin-3a 
treatment (Figure 3.1.6 E). The transcription levels of p53 were almost the same in Nutlin-3a 
treatment and untreated (DMSO) cells (Figure 3.1.6 E) but p53 protein levels in A2788 and 
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NIFK overexpression cells were higher in Nultlin-3a treatment (Figure 3.1.6 D). Interestingly, 
although the mRNA expression of GADD45 was induced by Nutlin-3a, the protein expression 
was decreased by Nultin-3a (Figure 3.1.6 D and Figure 3.1.6 E). These data suggest that future 
experiments will be required to identify why GADD45 protein level was decreased even though 
there was evidence that the transcription of GADD45 was induced by Nutlin-3a treatment. It 
might also be possible that NIFK protein plays a role to regulate the translation of GADD45 and 
that future experiments are required to identify the interaction of those two proteins. 
 
 
Figure 3.1.6 (D) Western Blot. A2780 cells and the NIFK overexpression cells were either treated with 
DMSO or Nutlin-3a (40 µM) for 24 hours. Whole cell lysates were collected from the various cell lines 
and were subjected to immunoblotting with different antibodies. The ß-actin blot served as the loading 
control for all samples.   
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Figure 3.1.6 (E) qRT-PCR. A2780 cells and the NIFK overexpression cells were either treated with 
DMSO (vehicle) or Nutlin-3a (40 µM) for 24 hours. The RNA was reverse-transcribed into cDNA and 
evaluation by qPCR to measure the transcript levels of various genes in the p53 networks. 
  





Forward Sequence Reverse Sequence 
MDM2 5'-TGCCAAGCTTCTCTGTGAAAG-3' 5'-TCCTTTTGATCACTCCCACC-3' 
GADD45 5'-GGAGAGCAGAAGACCGAAAG-3' 5'-AGGCACAACACCACGTTATC-3' 
p21 5'-ATGAAATTCACCCCCTTTCC-3' 5'-CCCTAGGCTGTGCTCACTTC-3' 
p53 5'-GTCCCAAGCAATGGATGATTT-3' 5'-GTTGTAGTGGATGGTGGTACAG-3' 
18S 5'-GCCCGAAGCGTTTACTTTGA-3' 5'-TCCATTATTCCTAGCTGCGGTATC-3' 
 
Table 3.1.3.  Lists of primer sequences used in quantitative reverse transcriptase polymerase chain 
reaction (qRT-PCR).  
 
 MDM2 is an E3 ubiquitin ligase, and our observation that endogenous NIFK expression 
decreases upon MDM2 induction by Nutlin-3a (Figure 3.1.6 D) raises a possibility that NIFK 
expression may be regulated by MDMD2. To test this possibility, we used siRNAs to knock 
down MDM2 expression in cells.  Cells were plated in 6-well plates for siRNA experiments. 
After 48 hours post infection with control siRNA or MDM2 siRNA, Nutlin-3a (10 µM) in fresh 
media was added to the cells. Following an additional 24 hours, cells were harvested and 
subjected to Western blot analysis.  The endogenous NIFK levels were increased in cells 
transfected with MDM2 siRNA compared to the cells transfected with the control siRNA (Figure 
3.1.6 F).  In untreated cells, the exogenous NIFK protein level was slightly increased in MDM2 
siRNA compare to control siRNA (Figure 3.1.6 F).  In Nultin-3a treated cells, the exogenous 
NIFK expression level was decreased in MDM2 siRNA (Figure 3.1.6 F).  It is possible that 
NIFK regulates MDM2 and the route of regulation is needed to explore in ovarian cancer.  The 
p53 and p21 protein levels were relatively remain unchanged but the slight decreased expression 
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were observed in full length NIFK expression Nutlin-3a treated cells upon MDM2 siRNA 
knockdown (Figure 3.1.6 F).  There was the change in p21 protein levels in NIFK-ΔRRM 
overexpression cells after MDM2 siRNA knockdown in Nutlin-3a treatment (Figure 3.1.6 F). In 
addition, future experiments are needed to investigate the mechanism of NIFK in ovarian cancer 
with wild-type p53.   
 
 
Figure 3.1.6 (F) Western Blot. A2780 cells and the NIFK overexpression cells were infected with either 
control siRNA or MDM2 siRNA for 48 hours and were then subjected to either treatment with DMSO or 
Nutlin-3a (10µM) for 24 hours. The whole cell lysates were collected from the treated cells and were 
subjected to immunoblot using the different antibodies shown above. The ß-actin blot served as the 
loading control for all samples. 
  
  










Table 3.1.4. Lists of Lists of MDM2 siRNA sequences used in transfection to A2780 and NIFK 
overexpression cells.  
 
3.1.7 Higher NIFK expression is associated with poor outcome in ovarian cancer patients.   
 We next determined the association between NIFK expression and clinical outcome in 
patients with ovarian cancer. Kaplan-Meier analyses of 1,657 ovarian tumor samples, provided 
by the online Kaplan-Meier (KM) plotter (Gyorffy et al. 2010), point out that in general higher 
expression of NIFK was associated with lower progression-free survival (PFS) and overall 
survival (OS) in ovarian cancer patients (Figure 3.1.7A and 3.1.7 B). The plots indicate that the 
ovarian cancers with higher NIFK expression are significantly associated with a poor response to 
the current chemotherapy, resulting in decreased progression-free and overall survival. These 
findings might be relevant towards improving our understand the pathogenesis of ovarian cancer 
given our forward genetic screening studies suggest a role of NIFK in a subset of ovarian cancer 
with wild-type p53.  
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Figure 3.1.7 Association between NIFK expression and clinical outcome. (A) Higher expression of 
NIFK in ovarian cancer is associated with poor overall survival. (B) Higher expression of NIFK in 
ovarian cancer is associated with early disease recurrence (progression-free survival).   
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4.1 Summary 
 We derived an ovarian cancer cDNA library from patient samples and used it in a 
forward genetic screen in TP53 wild-type ovarian cancer cells to identify the potential exogenous 
factors that negatively regulate p53 functions. First, we established an optimal transduction 
method to transduced retroviral particles into A2780 cells (Figure 3.1.2). Second, we established 
an optimal concentration of Nutlin-3a that can suppress clonogenic growth (Figure 3.1.3). Third, 
we established PCR conditions to rescue the transduced genes from the cDNA library (Figure 
3.1.4). These experiments were essential to establish the necessary steps for a successful 
screening of the cDNA library. From these studies we identified NIFK as a potential negative 
regulator of p53 activity. 
We also performed the colony formation assay using A2780 and NIFK overexpression 
A2780 cells (Figure 3.1.6). From the publish paper, FHA domain of NIFK is required to interact 
with Ki-67 protein and two phosphorylation sites Thr234 and Thr238 are needed for the 
interactions.  Change of those two phosphorylation sites to alanine will terminate the interaction 
between Ki-67 and NIFK proteins and we used the construct NIFK-T>A to find out what is the 
important function of those in ovarian cancer.  RNA reorganization motif (RRM) of NIFK is 
essential for the pre-rRNA processing and G1 progression (Pan et al. 2015).  We included all 
four different constructs in our experiment to find out the role of NIFK in ovarian cancer.  Our 
results showed that NIFK full length, NIFK-ΔKi-FHA, NIFK-ΔRRM, NIFK-T>A 
overexpressing cells are consistently more resistant to Nutlin-3a (Figure 3.1.6 A). We tested 
other genes that are transcriptionally regulated by p53, such as p21 and GADD45, by qRT-PCR 
and we found that there was no difference in these genes that are involved in cell cycle arrest 
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such as compare to A2780 and NIFK overexpression cells except GADD45. The GADD45 
transcription was regulated by p53 after Nultin-3a treatment but the opposite result was observed 
in Western Blot (Figure 3.1.6 D & 3.1.6 E). Furthermore, we found that higher NIFK 
overexpression is associated with poor overall survival and disease-free survival in ovarian 
cancer patients (Figure 3.1.7). Our study identified for the first time a potential negative 
regulator of p53 and its network in cell cycle arrest and cell growth. However, additional studies 
are required to confirm that NIFK can negatively regulates p53 protein functions.  Specifically, it 
will be important to identify the exact mechanism(s) of how NIFK regulates p53 functions and 
its network in ovarian cancer.  We tried to use siRNA NIFK in the experiments to explore the 
role of NIFK in ovarian cancer.  Unfortunately, NIFK knockdown with siRNA were 
unsuccessful due to very low efficiency in multiple set of siRNA.  We also looked for ovarian 
cancer cell lines which have either low level expression or no expression of NIFK.  All the 
ovarian cell lines we have showed the moderate to higher expression of NIFK by Western Blot 
(data not included).  From our immunofluorescent data, NIFK-ΔRRM showed that the 
localization of NIFK protein to nucleoli was terminated and NIFK-ΔRRM protein was 
accumulated in the cytoplasm (data not included).  From all of our experiment data pointed that 
NIFK is the novel gene that needs to investigate in detail to understand the mechanism in ovarian 
cancer.  Nevertheless, our studies suggest that NIFK can play a role in the pathogenesis of 
ovarian cancer patients with functional wild-type p53. 
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4.2 Discussion  
 The FHA domains found in kinases, phosphatase, kinesins and transcription factor 
indicate the wide variety of functions of this domain. The FHA domain is particularly important 
in cell cycle control, DNA damage repair and cell proliferation. The nucleolar protein NIFK 
(MKI67IP) has a Ki-67 FHA binding domain as identified from a yeast two-hybrid screen. One 
study suggested that NIFK played a role in cell proliferation in Ki-67 dependent manner via 
CK1α and ß-catenin (Lin et al. 2016). The interaction between NIFK and Ki-67 FHA domain 
requires the phosphorylation on both Thr234 and Thr238 of NIFK (Takagi et al. 2001). The other 
domain of NIFK is RRM (RNA recognition motif) domain and previous studies have shown that 
the RRM domain is able to bind to double-stranded DNA sequences (Newberry, Latifi, and 
Towler 1999). Also from other studies, the RRM domain appears to be involved in the protein-
protein interaction of post-transcriptional gene regulation as well as RNA recognition (Maris, 
Dominguez, and Allain 2005) (Kielkopf, Lucke, and Green 2004). All these studies along with 
our findings from the forward genetic screening indicate that NIFK is the candidate gene to study 
the cellular mechanism in ovarian cancer with functional p53 protein. The over-expressed NIFK 
cells were tested for its ability to promote growth under different concentrations of Nutlin-3a, 
and we found that NIFK-overexpressing cells formed colonies even in a higher concentration of 
Nutlin-3a (Figure 3.1.6). From our experiment, the protein level of GADD45 is slighter lower in 
NIFK overexpressed cells with Nutlin-3a treatment (Figure 3.1.6).  In addition, the deletion of 
RRM (RNA recognition motif) domain results in localization of protein to cytoplasm instead of 
nucleoli (data not included).  Our results raise the possibility that NIFK will play a role in tumor 
cell proliferation and may counteract the growth suppressive function of p53 protein. Additional 
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studies will be needed to further refine the function of NIFK in the development of certain forms 
of ovarian cancer. 
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